Lance Laing

833 citations

23 papers · 687 indexed · h-index 9

Surfaces, Coatings and Films top 10%
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 6
- RNA and protein synthesis mechanisms 5
- RNA Research and Splicing 4
- Advanced Biosensing Techniques and Applications 3
Biomedical Engineering
Atomic and Molecular Physics, and Optics
Biophysics
Oncology
- HER2/EGFR in Cancer Research 6
- Cancer Treatment and Pharmacology 3
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 6
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 4

Co-authors: David E. Draper Brian T. Cunningham Thomas C. Gluick Kathleen B. Hall Stephen Schulz E W Fine Fengqiu Wang Cheryl L. Baird
Cited by: Surfaces, Coatings and Films Molecular Biology Biomedical Engineering
Journals: Journal of Molecular Biology (3 papers)Cancer Research (3 papers)Journal of Clinical Oncology (2 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Lance Laing

22 papers receiving 660 citations

Peers

Countries citing papers authored by Lance Laing

Since Specialization

Citations

This map shows the geographic impact of Lance Laing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lance Laing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lance Laing more than expected).

Fields of papers citing papers by Lance Laing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lance Laing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lance Laing. The network helps show where Lance Laing may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Lance Laing, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lance Laing Line = papers co-authored together Lance Laing links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway Molecular Oncology ·Amit Kumar,Salmaan Khan,Stefano Rossetti,Jadran Šundrica,Ian A. MacNeil,Ann DeLaForest,S Dhankhar,Laura I. Davis,Kate Dufton,Eric Szilagyi,Ross A. Kopher,Stephen Schulz,Lance Laing	2024	4
2	An Open-Label Phase II Trial NCT03812393 to Evaluate the Efficacy and Safety of Neoadjuvant Neratinib Followed by Weekly Paclitaxel and Carboplatin Plus Neratinib in Early-Stage Triple-Negative Breast Cancer (TNBC) Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2) Elizabeth S. John,蔡岩松,Lance Laing,A. Kurka,Lee S. Schwartzberg,Gregory A. Vidal	2024	1
3	Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models npj Breast Cancer ·Stefano Rossetti,Jadran Šundrica,Amit Kumar,Salmaan Khan,Ian A. MacNeil,S Dhankhar,Ross A. Kopher,Stephen Schulz,Lance Laing	2024	14
4	Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib Cancers ·Jadran Šundrica,Stefano Rossetti,Amit Kumar,Anup Deshpande,Ian A. MacNeil,S Dhankhar,Lance Laing	2024	2
5	Abstract 4928: Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status Cancer Research ·Stefano Rossetti,Jadran Šundrica,Ian A. MacNeil,Ben A. Rich,S Dhankhar,Brian Sullivan,Lance Laing	2023	1
6	Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status. Journal of Clinical Oncology ·Adrish Sen,Salmaan Khan,Ian A. MacNeil,Benjamin E. Rich,S Dhankhar,Yushi Fujita and Jody L.Toquam,Stefano Rossetti,Kiell Naas,Lance Laing	2023	2
7	Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy Cell Communication and Signaling ·Ian A. MacNeil,Salmaan Khan,Amit Kumar,Sajjad Soltani,David J. Burns,and M. Veskovic,Lance Laing	2022	2
8	Abstract 342: Sub-group of HER2-negative breast cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors Cancer Research ·Salmaan Khan,Amit Kumar,E S Zenkova,Ian A. MacNeil,Jadran Šundrica,Sarah C. Mutka,Theodora Antareli,L. Brian Morris,Laura Milligan,A Ricardo,and M. Veskovic,Lance Laing	2021	2
9	Abstract 367: Sub-group of ovarian cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors Cancer Research ·Stefano Rossetti,Jadran Šundrica,Sullivan La,Shu Z. Wiley,Salmaan Khan,E S Zenkova,Ian A. MacNeil,and M. Veskovic,Lance Laing	2021	1
10	New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified Journal of Cancer Research and Clinical Oncology ·Ian A. MacNeil,David J. Burns,Benjamin E. Rich,Sajjad Soltani,孙娜娜,Carlos M. R. Sant’Anna,and M. Veskovic,Douglas M. Hawkins,Jodie Pietruska,Lance Laing	2020	5
11	Test identifies ovarian cancer patients with hyperactive c-Met and ErbB signaling tumors who may benefit from c-Met and pan-HER combination therapy. Journal of Clinical Oncology ·Lance Laing,Stefano Rossetti,E S Zenkova,Jadran Šundrica,Sullivan La,Salmaan Khan,Ian A. MacNeil,and M. Veskovic	2020	1
12	Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells BMC Cancer ·Βασιλική Μακρυγιάννη,David J. Burns,Benjamin E. Rich,Ian A. MacNeil,Abhijit Dandapat,Sajjad Soltani,忠義伊谷,and M. Veskovic,Carol A. Lange,Leo T. Furcht,Lance Laing	2017	14
13	A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity Oncotarget ·Βασιλική Μακρυγιάννη,David J. Burns,Benjamin E. Rich,Ian A. MacNeil,Abhijit Dandapat,Sajjad Soltani,忠義伊谷,and M. Veskovic,Leo T. Furcht,Carol A. Lange,Sara A. Hurvitz,Lance Laing	2016	3
14	Validation of an Optical Microplate Label-Free Platform in the Screening of Chemical Libraries for Direct Binding to a Nuclear Receptor Assay and Drug Development Technologies ·Laura Vela,Peter N. Lowe,C. Katharina Spieß,Lance Laing,Julie B. Stimmel,Lisa A. Orband‐Miller,Julio Martín	2011	4
15	Microplate-based, label-free detection of biomolecular interactions: applications in proteomics Expert Review of Proteomics ·Brian T. Cunningham,Lance Laing	2006	72
16	Label-Free Assays on the BIND System SLAS DISCOVERY ·Brian T. Cunningham,Teen‐Lee Pua,Stephen Schulz,Bo Lin,Cheryl L. Baird,C. Katharina Spieß,C. Hartwich,Fengqiu Wang,E W Fine,Lance Laing	2004	205
17	A Model of the Iron Responsive Element RNA Hairpin Loop Structure Determined from NMR and Thermodynamic Data Biochemistry ·Lance Laing,Kathleen B. Hall	1996	56
18	Thermodynamics of RNA unfolding: Stabilization of a ribosomal RNA tertiary structure by thiostrepton and ammonium ion Journal of Molecular Biology ·David E. Draper,Yanyan Xing,Lance Laing	1995	33
19	Stabilization of RNA Structure by Mg Ions Journal of Molecular Biology ·Lance Laing,Thomas C. Gluick,David E. Draper	1994	135
20	Thermodynamics of RNA Folding in a Conserved Ribosomal RNA Domain Journal of Molecular Biology ·Lance Laing,David E. Draper	1994	90

About Lance Laing

Lance Laing is a scholar working on Immunology and Allergy, Oncology, Radiology, Nuclear Medicine and Imaging, Reproductive Medicine and Pulmonary and Respiratory Medicine, having authored 23 papers that have together received 687 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (6 papers), HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), RNA and protein synthesis mechanisms (5 papers), Advanced Breast Cancer Therapies (4 papers), RNA Research and Splicing (4 papers), Cancer Treatment and Pharmacology (3 papers) and Advanced Biosensing Techniques and Applications (3 papers). The work is most often cited by research in Surfaces, Coatings and Films (61 citations), Molecular Biology (486 citations), Biomedical Engineering (167 citations), Atomic and Molecular Physics, and Optics (109 citations) and Biophysics (20 citations). Lance Laing has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include David E. Draper, Brian T. Cunningham, Thomas C. Gluick, Kathleen B. Hall, Stephen Schulz, E W Fine, Fengqiu Wang, Cheryl L. Baird, Bo Lin and Yanyan Xing. Their work appears in journals such as Journal of Molecular Biology, Cancer Research, Journal of Clinical Oncology, SLAS DISCOVERY and Molecular Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact